Stratasys Ltd. remains unconvincing as an investment, with persistent revenue declines and elusive profitability despite multi-year low share prices. Q4 revenue fell 7% year-over-year across all regions; adjusted EPS was $0.07, but GAAP losses and negative free cash flow persist. Management guides for modest 2025 revenue growth ($565–$575M) and EPS of $0.12, well below analyst expectations, highlighting slow margin recovery.

MINNETONKA, Minn. & REHOVOT, Israel--(BUSINESS WIRE)--Stratasys Ltd. (NASDAQ: SSYS) announced today that it has expanded its portfolio of additive manufacturing solutions across multiple industries with the introduction of new software and materials that expand applications of existing systems and improve ease of use for customers. New materials include: ULTEM™ 1010 filament for the F3300® printer, and PolyJet ToughONE™ White for Stratasys J3/J5™ printers, along with a new Measurement-Based War.

Stratasys, Ltd. (NASDAQ: SSYS - Get Free Report) has received an average recommendation of "Moderate Buy" from the five brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among

MINNETONKA, Minn. & REHOVOT, Israel--(BUSINESS WIRE)--Stratasys Ltd. (NASDAQ: SSYS) today announced that its parts-on-demand business, Stratasys Direct™, has been selected to take part in the U.S. Department of War's (DoW) Joint Additive Manufacturing Acceptability (JAMA) IV Pilot Parts Program, a multimillion-dollar initiative to accelerate qualification and deployment of 3D-printed parts across military platforms and systems. As a Program of Record for the U.S. Air Force and Naval Air Systems.

MINNETONKA, Minn. & REHOVOT, Israel--(BUSINESS WIRE)--Stratasys Ltd. (NASDAQ: SSYS) today announced that its TrueDent® resins have received CE marking as a Class IIa medical device, making them Europe's first high-esthetic, monolithic 3D-printed denture solution to achieve certification in the more than $2 billion market. This milestone enables broader regulated clinical use and expands patient access to polychromatic, monolithic 3D-printed dentures, removable partial dentures, and crowns and b.

Shares of Stratasys, Ltd. (NASDAQ: SSYS - Get Free Report) have received a consensus rating of "Moderate Buy" from the five brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1

SSYS beats Q4 EPS and revenue estimates. However, revenues drop 7% and profit plunges year over year.

Explore the exciting world of Stratasys (SSYS 7.45%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

Stratasys Ltd. (SSYS) Q4 2025 Earnings Call Transcript

MINNETONKA, Minn. & REHOVOT, Israel--(BUSINESS WIRE)--Stratasys Ltd. (Nasdaq: SSYS), announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the “SEC”). The annual report on Form 20-F, which contains Stratasys' audited annual financial statements for 2025, can be accessed on the SEC's website at http://www.sec.gov, as well as via the Company's investor relations website at http://investors.str.